Cytogenetic Abnormalities in Multiple Myeloma: Poor Prognosis Linked to Concomitant Detection in Random and Focal Lesion Bone Marrow Samples and Associated with High-Risk Gene Expression Profile

Documenti analoghi

• TP53 Deletion is Not an Adverse Feature in Multiple Myeloma Treated with Total Therapy 3
  di: Shaughnessy, John D, et al.
  Pubblicazione: (2009)
• International Staging System and Metaphase Cytogenetic Abnormalities in the Era of Gene Expression Profiling Data in Multiple Myeloma Treated with Total Therapy 2 and 3 Protocols
  di: Waheed, Sarah, et al.
  Pubblicazione: (2010)
• Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
  di: Pineda-Roman, Mauricio, et al.
  Pubblicazione: (2008)
• Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1
  di: Zangari, Maurizio, et al.
  Pubblicazione: (2008)
• The Arkansas approach to therapy of patients with multiple myeloma
  di: Barlogie, Bart, et al.
  Pubblicazione: (2007)